APA (7th ed.) Citation

MF, C., JJ, L., NJ, C., AB, H., MY, J., J, Z., . . . HA, Y. (2026). Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 21(3), 103505. https://doi.org/10.1016/j.jtho.2025.10.012

Chicago Style (17th ed.) Citation

MF, Chen, et al. "Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 21, no. 3 (2026): 103505. https://doi.org/10.1016/j.jtho.2025.10.012.

MLA (9th ed.) Citation

MF, Chen, et al. "Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 21, no. 3, 2026, p. 103505, https://doi.org/10.1016/j.jtho.2025.10.012.